Cancer Drugs

Revised Maximum Retail Prices (MRPs) of 1,364 anti-cancer formulations have come into effect from Monday, a move projected to save consumers an estimated Rs 3,540.38 crore annually, according to an official release. The National Pharmaceutical Pricing Authority (NPPA), functioning under the Department of Pharmaceuticals, capped trade margins on the MRP of 137 anti-cancer drugs based on recommendations submitted on October 17, 2026, by an Expert Committee constituted by the Directorate General of Health Services (DGHS), Ministry of Health & Family Welfare. According to the ministry, 85 pharmaceutical companies have reported revised MRPs for 1,364 anti-cancer formulations across 121 drugs as of November 8, 2026. Price reductions of over 50 per cent have been reported for 679 brands, with the highest price cut recorded at 96.45 per cent, the Ministry of Chemicals and Fertilizers: Department of Pharmaceuticals said in the release. The ministry stated that no chemist or hospital ...

Major innovator brands see no price reductions despite cuts of up to 93 per cent for some cancer medicines; patient groups say PAP exclusions and data gaps have diluted relief

The Supreme Court questioned steep hospital mark-ups on cancer medicines and medical consumables, criticised the Centre's pricing framework and reserved its verdict on a plea seeking tighter controls

Experts warn that the 30% trade-margin cap on 137 anti-cancer drugs may offer limited relief to patients as assistance programmes remain excluded from price calculations.

Partnership expands vaccine maker's push into cell and gene therapies; companies target commercialisation of blood cancer treatment by 2028

The NPPA's 30% trade margin cap on 137 oncology drugs, effective November 9, has drawn support from the pharma industry, while patient groups question its impact on affordability.

New prices set to come into effect from November 9, 2026; state drug controllers to monitor implementation

Bench questions steep mark-ups on medicines and medical devices; Centre says price regulation must balance affordability with availability

According to reports, the Centre has decided to cap trade margins for all non-scheduled anti-cancer drugs at 30 per cent of the MRP.

Move could cut MRPs by up to 70%, save patients ₹2,500 crore annually; comes amid SC scrutiny of high mark-ups

The Supreme Court said it was "absolutely shocking" that the printed MRP of an essential cancer drug was ₹27,000 when the price to the retailer was ₹2,700

Biocon jumped nearly 3% in Monday's trade after the company's Pertuzumab biosimilar drug received EMA CHMP recommendation for breast cancer care.

Researchers are exploring technologies that will allow scientists to observe living cancer cells in real time to help them improve understanding of the disease and accelerate drug discovery. Despite advances in genomics, artificial intelligence and precision medicine, scientists still rely heavily on studying cells after they have been chemically fixed or destroyed, providing only a static snapshot of an otherwise dynamic biological process. Experts now believe that understanding how living cells behave in real time could become one of the next frontiers in biomedical research, particularly in oncology, where cancer cells continuously evolve, adapt and develop resistance to treatment. Parmita Mishra, founder and CEO of San Francisco-based biotech start-up Precigenetics, said they are developing a technology platform that enables researchers to observe living cells continuously without dyes, labels or destructive sample preparation. The approach combines Raman spectroscopy, photonic

Providers say delayed payments, unexplained claim rejections and below-cost reimbursement for some cancer drugs are straining finances despite recently revised CGHS rates

A potential deal would carry regulatory risk because of concerns about how it might be assessed by US antitrust authorities under ‌President Donald Trump's administration

New company to raise capital for global clinical trials; Lupin to retain significant equity stake and provide seed funding

In the past seven trading days, the Nifty Pharma index outperformed the market by soaring 5.4 per cent, as compared to 0.1 per cent decline in the Nifty 50.

The tentative approval allows Lupin to market the generic prostate cancer treatment in the US after patent and exclusivity barriers expire

Biocon, Zydus, Dr Reddy's are among companies positioning for one of the largest biosimilar launches for cancer treatment

Alembic Pharmaceuticals Ltd on Friday said it has received tentative approval from the US health regulator for its generic version of cancer treatment drug Binimetinib tablets. The tentative approval by the US Food & Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) of Binimetinib tablets of strength 45 mg, Alembic Pharmaceuticals said in a regulatory filing. Based on USFDA's paragraph IV certifications list, Alembic is the sole first applicant to have filed its ANDA for Binimetinib Tablets, 45mg and upon final approval of this ANDA by the USFDA, the company may be eligible for 180 days of generic marketing exclusivity in the US, the company said. Alembic had previously received tentative approval for Binimetinib Tablets, 15mg, it added. Binimetinib in combination with encorafenib is used for the treatment of patients with unresectable or metastatic melanoma with resistance to specific targeted therapies in cancer. It is also indicated, in combination